203 related articles for article (PubMed ID: 32157747)
1. Endothelial-derived plasma exosome proteins in Alzheimer's disease angiopathy.
Abner EL; Elahi FM; Jicha GA; Mustapic M; Al-Janabi O; Kramer JH; Kapogiannis D; Goetzl EJ
FASEB J; 2020 Apr; 34(4):5967-5974. PubMed ID: 32157747
[TBL] [Abstract][Full Text] [Related]
2. Association between white matter hyperintensity and medial temporal atrophy at various stages of Alzheimer's disease.
Kandiah N; Chander RJ; Ng A; Wen MC; Cenina AR; Assam PN
Eur J Neurol; 2015 Jan; 22(1):150-5. PubMed ID: 25142829
[TBL] [Abstract][Full Text] [Related]
3. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
[TBL] [Abstract][Full Text] [Related]
4. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
5. Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer's dementia.
Zhao A; Li Y; Yan Y; Qiu Y; Li B; Xu W; Wang Y; Liu J; Deng Y
Transl Neurodegener; 2020 Aug; 9(1):30. PubMed ID: 32741361
[TBL] [Abstract][Full Text] [Related]
6. White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease.
Soldan A; Pettigrew C; Zhu Y; Wang MC; Moghekar A; Gottesman RF; Singh B; Martinez O; Fletcher E; DeCarli C; Albert M;
Neurology; 2020 Mar; 94(9):e950-e960. PubMed ID: 31888969
[TBL] [Abstract][Full Text] [Related]
7. Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment.
Newton P; Tchounguen J; Pettigrew C; Lim C; Lin Z; Lu H; Moghekar A; Albert M; Soldan A;
J Alzheimers Dis; 2023; 92(1):323-339. PubMed ID: 36744337
[TBL] [Abstract][Full Text] [Related]
8. Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid.
Jia L; Qiu Q; Zhang H; Chu L; Du Y; Zhang J; Zhou C; Liang F; Shi S; Wang S; Qin W; Wang Q; Li F; Wang Q; Li Y; Shen L; Wei Y; Jia J
Alzheimers Dement; 2019 Aug; 15(8):1071-1080. PubMed ID: 31422798
[TBL] [Abstract][Full Text] [Related]
9. Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease.
Chiu MJ; Yang SY; Horng HE; Yang CC; Chen TF; Chieh JJ; Chen HH; Chen TC; Ho CS; Chang SF; Liu HC; Hong CY; Yang HC
ACS Chem Neurosci; 2013 Dec; 4(12):1530-6. PubMed ID: 24090201
[TBL] [Abstract][Full Text] [Related]
10. White matter hyperintensities and cognition across different Alzheimer's biomarker profiles.
Lam S; Lipton RB; Harvey DJ; Zammit AR; Ezzati A;
J Am Geriatr Soc; 2021 Jul; 69(7):1906-1915. PubMed ID: 33891712
[TBL] [Abstract][Full Text] [Related]
11. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
12. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
13. Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease.
Li WW; Shen YY; Tian DY; Bu XL; Zeng F; Liu YH; Chen Y; Yao XQ; Li HY; Chen DW; Zhou FY; Yang H; Li QM; Bao WQ; Guan YH; Zhou HD; Jin RB; Wang YJ
J Alzheimers Dis; 2019; 69(1):169-178. PubMed ID: 30958377
[TBL] [Abstract][Full Text] [Related]
14. Serum Tau Proteins as Potential Biomarkers for the Assessment of Alzheimer's Disease Progression.
Nam E; Lee YB; Moon C; Chang KA
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679907
[TBL] [Abstract][Full Text] [Related]
15. Plasma soluble TREM2 is associated with white matter lesions independent of amyloid and tau.
Tsai HH; Chen YF; Yen RF; Lo YL; Yang KC; Jeng JS; Tsai LK; Chang CF
Brain; 2021 Dec; 144(11):3371-3380. PubMed ID: 34515756
[TBL] [Abstract][Full Text] [Related]
16. Changes in Plasma Amyloid and Tau in a Longitudinal Study of Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
Chen TB; Lai YH; Ke TL; Chen JP; Lee YJ; Lin SY; Lin PC; Wang PN; Cheng IH
Dement Geriatr Cogn Disord; 2019; 48(3-4):180-195. PubMed ID: 31991443
[TBL] [Abstract][Full Text] [Related]
17. Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study.
Fiandaca MS; Kapogiannis D; Mapstone M; Boxer A; Eitan E; Schwartz JB; Abner EL; Petersen RC; Federoff HJ; Miller BL; Goetzl EJ
Alzheimers Dement; 2015 Jun; 11(6):600-7.e1. PubMed ID: 25130657
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
19. Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer's disease: a cross-sectional analysis from the SILCODE study.
Sheng C; Yang K; He B; Du W; Cai Y; Han Y
Alzheimers Res Ther; 2022 Feb; 14(1):35. PubMed ID: 35164860
[TBL] [Abstract][Full Text] [Related]
20. Peripheral Markers of Vascular Endothelial Dysfunction Show Independent but Additive Relationships with Brain-Based Biomarkers in Association with Functional Impairment in Alzheimer's Disease.
Drake JD; Chambers AB; Ott BR; Daiello LA;
J Alzheimers Dis; 2021; 80(4):1553-1565. PubMed ID: 33720880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
